After selling Pathway Oncology and AKTivate to VHL for lofty sums does Paul Hopper really need/deserve to have his directorial pay doubled to $180k.
- Forums
- ASX - By Stock
- VHL
- Ann: Prescient completes acquisition of AKTivate Therapeutics
Ann: Prescient completes acquisition of AKTivate Therapeutics, page-2
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)